Karkinos Healthcare, SOPHiA GENETICS to advance India cancer research

Karkinos will utilise the SOPHiA DDM Platform for the treatment of myeloid cancer and lymphoma.

India-based cancer care technology network Karkinos Healthcare has partnered with medicine software company SOPHiA GENETICS to utilise the latter’s SOPHiA DD Platform for the improvement of cancer testing and research for blood cancers and tumours.

The initiative to advance cancer research and personalised cancer care aims to serve low and middle-income countries.

The SOPHiA DDM Platform allows monitoring of a wide array of genomic variants, applying machine learning algorithms for the detection of rare and challenging cancer cases. Through the partnership, Karkinos Healthcare will apply SOPHiA GENETICS' technology to broaden its offerings, research resources and pipeline for blood cancers, such as myeloid cancer and lymphoma.

“It is our continued goal to improve health outcomes for patients globally by expanding access to precision oncology and equipping local health institutions with the tools and technology needed to practice data-driven medicine,” Dr. Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, said.

ALSO READ: Nanyang Polytechnic develops AI capability to detect human falls

Karkinos, with its in-house Distributed Cancer Care Network, will also use the specialties of SOPHiA GENETICS for the analysis of solid tumours for cancers like ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers.

Through their NGS-based workflows for streamlining processes, researchers from Karkinos can acquire high-quality and reproducible data to speed up their clinical research studies and improve the application of precision medicine.

“This alliance will have the potential to generate evidence and world-class research for faster and accurate diagnosis and better control and management of cancers, particularly for the underprivileged population of our country,” Dr. R Venkataramanan, Founder and CEO of Karkinos Healthcare, said.